Sage drops dalzanemdor for Parkinson’s after trial flop
Sage Therapeutics has suffered another disappointment after deciding …
Newsletters and Deep Dive digital magazine
Sage Therapeutics has suffered another disappointment after deciding …
When it comes to patient-facing AI in healthcare, ChatGPT, with its …
Eli Lilly’s diabetes and obesity therapy tirzepatide could find a use …
Questions of supply chain security and resiliency have been growing …
A proposed order by the Federal Trade Commission (FTC) would impose a …
MaaT Pharma’s quest to bring a microbiota-based therapy to market has …
Artificial intelligence (AI) is poised to transform Medical …
GSK has unveiled the data for its novel antibiotic gepotidacin as a …
Shares in Intra-Cellular Therapies rose sharply after it reported …
And we’re live on site all day again on Day Two of Reuters Pharma …
2024 is a pivotal year for the US healthcare sector. America remains …
The FDA has started a review of GSK’s five-in-one meningococcal …
Eli Lilly’s diabetes and obesity therapy tirzepatide could find a use as a treatment for obstructive sleep apnoea (OSA) after hitting the mark in a pair of phase 3 trials.
Explore “Innovation as Strategy” framework, providing a guide for employing innovative strategies in life sciences.
Over the last five years, a confluence of trends have combined to reshape the reality of clinical research. COVID-19 pushed decentralised trials into the mainstream.
It will come as no surprise to anyone in the healthcare space that doctors today are under an inordinate amount of pressure.
We are living in an era of unprecedented advances in cancer treatments with transformative therapies being regularly approved.
2024 is a pivotal year for the US healthcare sector.
The Industry’s Only Definitive Forum for Preclinical Heart Failure Drug Development